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Abstract
Background The CONSORT statement is intended to improve reporting
of randomised controlled trials and focuses on minimising the risk of
bias (internal validity). The applicability of a trial’s results (generalisability
or external validity) is also important, particularly for pragmatic trials. A
pragmatic trial (a term first used in 1967 by Schwartz and Lellouch) can
be broadly defined as a randomised controlled trial whose purpose is to
inform decisions about practice. This extension of the CONSORT
statement is intended to improve the reporting of such trials and focuses
on applicability.
Methods At two, two-day meetings held in Toronto in 2005 and 2008,
we reviewed the CONSORT statement and its extensions, the literature
on pragmatic trials and applicability, and our experiences in conducting
pragmatic trials.
RecommendationsWerecommendextendingeightCONSORTchecklist
items for reporting of pragmatic trials: the background, participants,
interventions, outcomes, sample size, blinding, participant flow, and
generalisability of the findings. These extensions are presented, along
with illustrative examples of reporting, and an explanation of each
extension. Adherence to these reporting criteria will make it easier for
decision makers to judge how applicable the results of randomised
controlled trials are to their own conditions. Empirical studies are needed
to ascertain the usefulness and comprehensiveness of these CONSORT
checklist item extensions. In the meantime we recommend that those
who support, conduct, and report pragmatic trials should use this
extension of the CONSORT statement to facilitate the use of trial results
in decisions about health care.
Randomisedcontrolledtrialsareusedtoassessthebenefitsand
harms of interventions in health care. If conducted properly,
they minimise the risk of bias (threats to internal validity),
particularly selection bias.
1 2 There is, however, considerable
evidence that trials are not always well reported,
3 4 and this can
beassociatedwithbias,suchasselectivereportingofoutcomes.
5
The usefulness of a trial report also depends on the clarity with
which it details the relevance of its interventions, participants,
outcomes, and design to the clinical, health service, or policy
question it examines. Furthermore, a trial may be valid and
useful in the healthcare setting in which it was conducted but
have limited applicability (also known as generalisability or
external validity) beyond this because of differences between
the trial setting and other settings to which its results are to be
extrapolated.
SchwartzandLellouch
6coinedtheterms“pragmatic”todescribe
trials designed to help choose between options for care, and
“explanatory” to describe trials designed to test causal research
hypotheses—forexample,thataninterventioncausesaparticular
biological change. Table 1⇓ shows some key differences
between explanatory and pragmatic trials. Table 2⇓ compares
a trial that was highly explanatory in attitude
7 with one that was
highlypragmatic.
8Thereisacontinuumratherthanadichotomy
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RESEARCH METHODS & REPORTINGbetweenexplanatoryandpragmatictrials.Infact,Schwartzand
Lellouch characterised pragmatism as an attitude to trial design
rather than a characteristic of the trial itself. The pragmatic
attitude favours design choices that maximise applicability of
the trial’s results to usual care settings, rely on unarguably
important outcomes such as mortality and severe morbidity,
and are tested in a wide range of participants.
9-11 As Schwartz
and Lellouch wrote: “Most trials done hitherto have adopted
the explanatory approach without question; the pragmatic
approach would often have been more justifiable.”
6
Calls have been made for more pragmatic trials in general,
6-13
and in relation to specific clinical problems.
14-16 Articles have
been published discussing the characteristics and value of
pragmatic trials
17-35 or proposing improvements in the design
and conduct of these trials.
36-38 Patients, advocacy groups,
clinicians, systematic reviewers, funders, and policymakers
want to use the results of randomised controlled trials. As such,
a clear description of the design and execution of the trial, the
intervention and comparator, and the setting in which health
care is provided may simplify their decision on the likely
benefits, harms, and costs to be expected when implementing
the intervention in their own situation. There is, however, no
accepted standard to guide reporting on the aspects of design
and conduct of trials that affect their usefulness for decision
making, particularly considerations that would affect the
applicability of the results.
We propose here guidance for reporting pragmatic trials, as a
specific extension of the CONSORT statement. Our aim is to
identify information which, if included in reports of pragmatic
trials, will help users determine whether the results are
applicable to their own situation and whether the intervention
might be feasible and acceptable. Reporting this information is
crucial for any trial that is intended to inform decisions about
practice.
CONSORT initiative
The original CONSORT statement (www.consort-statement.
org), last revised in 2001, was developed by clinical trialists,
methodologists, and medical journal editors to help improve
the reporting of parallel (two) group randomised trials.
39 The
objective of the statement is to enable readers to critically
appraiseandinterprettrialsbyprovidingauthorswithguidance
about how to improve the clarity, accuracy, and transparency
of their trial reports. It consists of a 22-item checklist and a
diagram, detailing the flow of participants through the trial. It
is a living document that is updated as needed, incorporating
new evidence.
40 The guidelines have been endorsed by more
than 300 journals,
41 and by several editorial groups, including
the International Committee of Medical Journal Editors.
42 The
CONSORT statement has been translated into several
languages.
43 Since its original publication in 1996 the quality
of reports of controlled trials has improved.
44
The CONSORT recommendations are intentionally generic,
and necessarily do not consider in detail all types of trials.
Extensions of the CONSORT statement have been developed
for non-inferiority and equivalence,
45 cluster randomised
designs,
46reportingofabstracts,
47dataonharms,
48trialsofherbal
interventions,
49 and of non-pharmacological interventions,
50 51
but not yet for the reporting of pragmatic trials, although some
issues pertaining to pragmatic trials were discussed in the
CONSORT explanation and elaboration paper.
4
Methods
In January 2005 and in March 2008, we held two-day meetings
inToronto,Canada,todiscusswaystoincreasethecontribution
of randomised controlled trials to healthcare decision making,
focusing on pragmatic trials. Participants included people with
experienceinclinicalcare,commissioningresearch,healthcare
financing, developing clinical practice guidelines, and trial
methodology and reporting. Twenty four people participated in
2005and42in2008,includingmembersoftheCONSORTand
Pragmatic Trials in Healthcare (Practihc) groups.
52
Afterthe2005meetingadraftrevisedchecklistfortheextension
was circulated to a writing group, including some of those
invited to the meeting but unable to attend. After several
revisions the writing group produced a draft summary paper.
At the 2008 meeting the draft was discussed and modified. It
wascirculatedtotheCONSORTgroupforfeedback,modified,
and submitted for publication.
Recommendationsforreportingpragmatic
trials
Meeting participants agreed that no items needed to be added
to the CONSORT checklist and that the flow diagram did not
need modification. However, participants felt that eight items
(2-4, 6, 7, 11, 13, and 21) needed additional text specific to the
reportingofpragmatictrials(seetable3⇓).Althoughparticipants
discussed additional text for item 1 of the checklist
(title/abstract), principally adding the word pragmatic to the
titleorabstract,wedecidedagainstmakingthisrecommendation
because it may reinforce the misconception that there is a
dichotomybetweenpragmaticandexplanatorytrialsratherthan
a continuum. We elected not to extend item 5 (objectives),
although we would encourage trialists to report the purpose of
the trial in relation to the decisions that it is intended to inform
and in which settings; we have included this recommendation
in connection with the extension of item 2 (background).
For each of the eight items we present the standard CONSORT
text and additional guidance, an example of good reporting for
the item, and an explanation of the issues. The selection of
examples is illustrative for a specific item and should not be
interpreted as a marker of quality for other aspects of those trial
reports. The suggestions in this paper should be seen as
additional to the general guidance in the main CONSORT
explanatory paper and where relevant, other CONSORT
guidance.
Item 2: introduction; background
Scientific background and explanation of rationale
Extension for pragmatic trials: Describe the health or health
serviceproblemthattheinterventionisintendedtoaddress,and
otherinterventionsthatmaycommonlybeaimedatthisproblem.
Example (a): Describe the health or health service problem
which the intervention is intended to address—“Although
interventions such as telephone or postal reminders from
pharmacistsimprovecompliancetheireffectonclinicaloutcome
is not known. We investigated whether periodic telephone
counselling by a pharmacist . . . reduced mortality in patients”
receiving polypharmacy.
53
Explanation—Users of pragmatic trial reports seek to solve a
health or health service problem in a particular setting. The
problem at which the intervention is targeted should thus be
described. This enables readers to understand whether the
problem confronting them is similar to the one described in the
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Ideally, the report should state that the trial is pragmatic in
attitude (and why) and explain the purpose of the trial in
relationship to the decisions that it is intended to inform and in
which settings.
Example (b): Describe other interventions that may commonly
be aimed at this problem—“Sublingual buprenorphine is
increasinglybeingprescribedbyGeneralPractitionersforopiate
detoxification, despite limited clinical and research evidence.
Comparing methadone, dihydrocodeine and buprenorphine it
is important to note several factors which may impact upon
prescribing and use of these agents”.
54
Explanation—Thebackgroundofthetrialreportshouldmention
theinterventionunderinvestigationandtheusualalternative(s)
inrelevantsettings.Tohelpplacethetrialinthecontextofother
settings authors should explain key features that make the
intervention feasible in their trial setting and elsewhere (such
as, the widespread availability of the trial drug, the availability
of trained staff to deliver the intervention, electronic databases
that can identify eligible patients).
Item 3: methods; participants
Eligibility criteria for participants and the settings
and the locations where the data were collected
Extension for pragmatic trials: Eligibility criteria should be
explicitly framed to show the degree to which they include
typicalparticipantsand,whereapplicable,typicalproviders(eg,
nurses), institutions (eg, hospitals), communities (or localities
eg,towns)andsettingsofcare(eg,differenthealthcarefinancing
systems).
Examples—“ThestudypopulationincludedallNationalHealth
System physicians in the Northern Region of Portugal except
forthosenotinvolvedinanyclinicalactivity(eg,administrators,
laboratory analysis); those working in substance abuse and
rehabilitationcentersorspecialtyhospitals(becausetheycover
multiple geographical areas); and those working at the regional
pharmacosurveillancecenteroranydepartmenthavingaspecific
voluntary ADR reporting program.”
55
“Our study took place in the three public hospitals (totalling
850 beds) in southern Adelaide, Australia, with a regional
population of about 350 000. In Australia, entry to long term
care(nursinghome)canoccuronlyafteranindependentclinical
assessment by the aged care assessment team (ACAT), who
determine level of dependency.”
56
Explanation—Treatments may perform better when evaluated
among selected, highly adherent patients with severe but not
intractable disease and few comorbidities. Reports of these
restricted trials may be of limited applicability. Excessively
stringentinclusionandexclusioncriteriareducetheapplicability
of the results and may result in safety concerns,
57 so the method
of recruitment should be completely described. This stringency
seems to be reducing over time but remains a problem.
58
In some trials the unit of randomisation and intervention might
be healthcare practitioners, communities, or healthcare
institutionssuchasclinics(thatis,clusterrandomisedpragmatic
trials). In these trials volunteer institutions may be atypically
wellresourcedorexperienced,successfulinnovators.Sincethe
feasibility and success of an intervention may depend on
attributes of the healthcare system and setting, reporting this
information enables readers to assess the relevance and
applicability of the results in their own, possibly different,
settings.
Item 4: methods; interventions
Precise details of the interventions intended for
each group and how and when they were actually
administered.
Extension for pragmatic trials: Describe extra resources added
to (or resources removed from) usual settings in order to
implement the intervention. Indicate if efforts were made to
standardisetheinterventionoriftheinterventionanditsdelivery
wereallowedtovarybetweenparticipants,practitionersorstudy
sites. Describe the comparator in similar detail to the
intervention.
Example: (a) Describe extra resources added to (or resources
removed from) usual settings in order to implement the
intervention—“The hospitals and a private long term care
providerdevelopedandrantheoff-sitetransitionalcarefacility,
which was 5-25 km from the study hospitals. The private
provider supplied accommodation, catering, cleaning, nursing
(5.0 full time equivalents in 24 hours), and career staff (10.0
full time equivalents in 24 hours) while the hospitals provided
the allied health staff (4.4 full time equivalents), medical staff,
and a transitional care nurse coordinator (1.0 full time
equivalent). The whole team assessed all patients on admission
to the transitional care unit and had weekly case conferences.
Specialist medical staff visited the site for the case conferences
andreviewedalladmissions.On-callmedicalcarewasavailable
24 hours a day.”
56
Explanation—If the extra resources to deliver the intervention
are not described, readers cannot judge the feasibility of the
interventionintheirownsetting.Whenrelevant,authorsshould
report details (experience, training etc) of those who delivered
the intervention
51 and its frequency and intensity. If
multicomponent interventions are being evaluated, details of
the different components should be described.
Example: (b) Indicate if efforts were made to standardise the
intervention or if the intervention and its delivery were allowed
tovarybetweenparticipants,practitionersorstudysites—“Two
trainedleadersintroducedastructuredsequenceoftopicsusing
a collaborative approach. All leaders had run at least one
previous group. Throughout the 12 week programme leaders
received three hours of supervision each week from a certified
trainer.
59
Explanation—In explanatory trials the intervention is
standardised, and thus the results may not apply under usual
conditions of care where no such standardisation is enforced.
Pragmatic trials are conducted in typical care settings, and so
care may vary between similar participants, by chance, by
practitioner preference, and according to institutional policies.
60
Forpragmatictrials,effortsthatmayreducethisnaturalvariation
in the intervention and its delivery should be described.
However, if reducing variation in a care process or shifting
practice patterns is itself the main purpose of the intervention,
this should be explicit in the title, abstract, and introduction.
Regardless of the extent to which the intervention was
standardised, pragmatic trials should describe the intervention
in sufficient detail that it would be possible for someone to
replicateit,orincludeareferenceorlinktoadetaileddescription
of the intervention. Unfortunately, this information is often
lacking in reports of trials.
61
Examples: (c) Describe the comparator in similar detail to the
intervention—“Standard advice was given as for the naproxen
group.Participantswereprovidedwithcocodamolforadditional
painreliefandaninformationleafletabout“tenniselbow”based
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specific treatment recommendations.”
62
“Womenassignedtothecontrolgroupreceivedusualcarefrom
thehealthcareteamandcompletedalloutcomemeasuresonthe
sametimeframeastheinterventiongroup.Afterrandomisation,
this group received a two page leaflet entitled “Exercise after
cancer diagnosis,” which provided safe guidelines. After the
six month follow-up, these women were helped to construct
their own personalised exercise plan and invited to join a local
general practice exercise referral scheme.”
63
Explanation—In a randomised controlled trial the effects of the
intervention are always related to a comparator. To increase
applicability, and feasibility, pragmatic trials often compare
new interventions to usual care. The chosen comparator should
be described in sufficient detail for readers to assess whether
the incremental benefits or harms reported are likely to apply
in their own setting, where usual care may be more, or less,
effective.
Item 6: methods; outcomes
Clearly defined primary and secondary outcome
measures, and, when applicable, any methods
used to enhance the quality of measurements
(eg, multiple observations, training of assessors)
Extensionforpragmatictrials:Explainwhythechosenoutcomes
and, when relevant, the length of follow-up are considered
important to those who will use the results of the trial.
Example—“The patient-based outcomes used in the evaluation
wereselectedonthebasisofempiricalevidencefromconsumers
aboutthemostimportantoutcomesfromSDM[shareddecision
making] and risk communication.”
64
The total number of days off work in the year after inclusion
was calculated for each patient. Days off were defined as days
100% compensated by the NIA [National Insurance
Administration]. Thus, days on ASL [Active Sick Leave] were
considered as days absent. After a full year of sick leave,
administrative proceedings are initiated to transfer the
beneficiary to other measures of rehabilitation or disability
pension within the NIA system. One year of absence was
therefore a proxy measure for long-term disability.”
65
Explanation—The primary outcome(s)
66 in pragmatic trials are
chosentoberelevanttotheparticipantsandkeydecisionmakers
at whom the trial is aimed. The length of follow-up should be
appropriate to the decision the trial is designed to inform. If the
target decision makers are patients and their clinicians, the
primary outcome is likely to be a health outcome, while trials
aimed at policymakers and institutional leaders may focus on
a process or system efficiency or equity outcome. Explicitly
indicating that the chosen outcome is important to decision
makers, and specifying the decision makers to whom it was
important will assist other readers to decide whether the results
are relevant to them.
Item 7: methods; sample size
How sample size was determined; when
applicable, explanation of any interim analyses
and stopping rules
Extension for pragmatic trials: If calculated using the smallest
difference considered important by the target decision maker
audience(theminimallyimportantdifference)thenreportwhere
this difference was obtained.
Example—“Therewerenopreviousdatausingthemainoutcome
measure on which to base the sample size calculation, and
therefore the sample size was calculated on the number of days
with URTI [upper respiratory tract infection]. It was decided,
in line with other rigorous pragmatic studies that the smallest
difference worth detecting was a 20% reduction in number of
days with URTI.”
67
Explanation—Theminimallyimportantdifference(MID)isthe
size of a change in the primary outcome which would be
important to the key decision making audience. The MID may
differbetweensettings,consequentlyreadersneedtoknowwhat
MIDwasconsideredimportantinthetrialsetting,andbywhom,
to contrast with their own expectations.
Item 11: methods; blinding (masking)
Whether participants, those administering the
interventions, and those assessing the outcomes
were blinded to group assignment
Extension for pragmatic trials: If blinding was not done, or was
not possible, explain why.
Example—“Randomisation was done by telephone to an
interactive voice response system. We entered and managed all
data in an anonymised format; we held data on patient contacts
and other administrative data in a separate database. The study
wasapragmatic,randomised,prospective,opentrial.Inexercise
studies, blinding the participants to allocation is not possible.
We took steps to blind the evaluation of outcomes by having
questionnaire responses in sealed envelopes and ensuring that
outcome measures were taken by researchers who were not
involved in exercise classes.”
63
Explanation—In explanatory trials blinding
68 prevents belief in
the effectiveness of the intervention (by participant, clinician
and/or assessor) from confounding the causal link between the
intervention and the primary outcome. In pragmatic trials, as in
the real world delivery of care, blinding of participants and
clinicians may be impossible. Belief (or disbelief) in the
intervention,extraenthusiasmandeffort(orless),andoptimism
(or pessimism) in the self-assessment of outcomes may thus
addto(ordetractfrom)theeffectsofanintervention.Pragmatic
trials may incorporate these factors into the estimate of
effectiveness, rendering the findings more applicable to usual
care settings. Authors should speculate on the effect of any
suspected modifying factors, such as belief in the intervention,
in the discussion (item 20). Moreover, in pragmatic trials, it is
still desirable and often possible to blind the assessor or obtain
an objective source of data for evaluation of outcomes.
Item 13: results; participant flow
Flow of participants through each stage (a
diagram is strongly recommended). Specifically,
for each group report the numbers of participants
randomly assigned, receiving intended treatment,
completing the study protocol, and analyzed for
the primary outcome. Describe protocol
deviations from study as planned, together with
reasons
Extension for pragmatic trials: The number of participants or
unitsapproachedtotakepartinthetrial,thenumberwhichwere
eligible and reasons for non-participation should be reported.
Example—“Thesepracticesascertained3392registeredpatients
withParkinson’sdisease;3124wereeligibleforstudyofwhom
1859(59.5%)agreedtoparticipate(fig3).Twenty-threepatients
died during recruitment, leaving 1836 patients when the
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tracedattheNHScentralregistryandarethereforenotincluded
in mortality analyses”.
69
Explanation—The more similar the participants, practitioners,
or other units of intervention or randomisation are to those in
usual care, the more likely that the results of the trial will be
applicable to usual care. Consequently the text and/or the trial
flow diagram should mention, if known, the number of
participants or units approached to take part in the trial, the
number whom were eligible, and reasons for non-participation.
Although this information is requested in the CONSORT
statement, the need for it is greater when reporting a pragmatic
trial.
Item 21: generalisability (applicability, external
validity)
Generalisability of the trial findings
Extension for pragmatic trials: Describe key aspects of the
setting which determined the trial results. Discuss possible
differences in other settings where clinical traditions, health
serviceorganisation,staffing,orresourcesmayvaryfromthose
of the trial.
Examples—“The intervention was tailored to the specific study
populationandmaynotbeaseffectiveinadifferentgroup.The
positive results may reflect in part unique aspects of the
Portuguesehealthcaresystemortheregionalphysicianculture.
Willingness to report adverse drug reactions may be less in
countries in which there is greater concern about malpractice
liability.”
55
“The incentive for implementing the clinical pathway will be
different for a single-payer third-party system, as exists in
Canada, in which costs of the pathway and offsetting hospital
costs are realized by the same payer, than for a multiple payer
system as exists in the United States, in which hospital cost
offsetswillberealizedbythehospitalandnotthenursinghome
payer.”
70
Explanation—The usefulness of the trial report is critically
dependent on how applicable the trial and its results are and
how feasible the intervention would be. The authors are well
placedtosuggesthowfeasibletheinterventionmightbe,which
aspects of their setting were essential to achieve the trial result,
and how that result might differ in other settings. The
applicability of the study result could be encapsulated here by
referencetothesetting(isitausualcaresetting),theparticipants
andproviders(howselectedwerethey),intensityofintervention
and follow up (how much like usual care was this), adherence
totheinterventionandwhethereffortsweremadetostandardise
itsdelivery,theuseofintentiontotreatanalysis,andtheamount
oflosstofollowup.Feasibilitycanbeencapsulatedbyreference
to economic, political, and logistic barriers to implementation
andbytherangeofsettingsandsocietiesinwhichthesebarriers
would be low.
Discussion
As demand rises for more pragmatic trials to inform real world
choices,
13 so too does the need to ensure that the results are
clearlyreported.Readersneedtobeabletoevaluatethevalidity
of the results, the extent to which they are applicable to their
settings, and the feasibility of the tested interventions. The
existing CONSORT statement applies fully and directly to
pragmatic trials. Here we have proposed extensions for eight
items in the statement to make more explicit the important
attributes of pragmatic trials and thus to ease the task of users
in assessing feasibility, relevance, and likely effects of the
intervention in their own setting.
Wereachedconsensusthatthetrialresultsarelikelytobemore
widelyapplicableiftheparticipants,communities,practitioners,
or institutions were not narrowly selected; if the intervention
wasimplementedwithoutintenseeffortstostandardiseit;ifthe
comparator group received care or other interventions already
widely used; and if the outcomes studied were of importance
to the relevant decision makers. The intervention needs to be
precisely described if readers are to be able to assess its
feasibility.
The multiplicity and independence of the elements constituting
the design of pragmatic trials guarantee that pragmatism is not
an all or none attribute; rather, it might be best conceived as a
continuumalongseveraldimensions.Forexample,arandomised
trialcouldhavebroadinclusioncriteriaforparticipantsbutrely
primarily on a short term, physiological outcome rather than
one that is more meaningful to the participants. Alternatively,
a trial might include a wide range of participants, meaningfully
assess the effect, but evaluate an intervention that is enforced
or tightly monitored and thus not widely feasible. Other
permutations probably exist. It is not the case that more
pragmatic is always better; a trial’s design should be such that
the results will meet the needs of the intended users. A trial
intendedtoinformaresearchdecisionaboutthebiologicaleffect
of a new drug is likely to be more explanatory in design. At a
later date, a trial of that same drug aimed at helping patients,
practitioners, or policymakers to decide whether it should be
prescribed is likely to be more pragmatic in design. To help
display this multidimensionality, we have developed of a tool,
primarily intended to be used in designing a trial, for
characterising where it will stand along the
pragmatic-explanatory continuum in relation to each design
decision.
71
We hope that these reporting guidelines will help editors,
reviewers, trialists, and policy makers in reporting, reviewing,
and using pragmatic trials. Journals that have endorsed the
CONSORT statement could also support CONSORT for
pragmatic trials, by including reference to this extension paper
in the journal’s instructions to authors. We also invite editorial
groups to consider endorsing the CONSORT extension for
pragmatic trials and encourage authors to adhere to it. Up to
date versions of all CONSORT guidelines can be found on the
CONSORT website (www.consort-statement.org).
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RESEARCH METHODS & REPORTINGTables
Table 1| Key differences between trials with explanatory and pragmatic attitudes, adapted from a table presented at the 2008 Society for
Clinical Trials meeting by Marion Campbell, University of Aberdeen
Effectiveness—does the intervention work when used in normal
practice?
Efficacy—can the intervention work? Question
Normal practice Well resourced, “ideal” setting Setting
Little or no selection beyond the clinical indication of interest Highly selected. Poorly adherent participants and those with conditions
which might dilute the effect are often excluded
Participants
Applied flexibly as it would be in normal practice Strictly enforced and adherence is monitored closely Intervention
Directly relevant to participants, funders, communities, and healthcare
practitioners
Often short term surrogates or process measures Outcomes
Direct—trial is designed to meet needs of those making decisions
about treatment options in setting in which intervention will be
implemented
Indirect—little effort made to match design of trial to decision making
needs of those in usual setting in which intervention will be
implemented
Relevance to practice
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RESEARCH METHODS & REPORTINGTable 2| Comparison of trial that was highly explanatory in attitude with trial that was highly pragmatic
Highly pragmatic attitude (Thomas et al
8) Highly explanatory attitude (NASCET
7)
Does a short course of acupuncture delivered by a qualified
acupuncturist reduce pain in patients with persistent
non-specific low-back pain?
Among patients with symptomatic 70-99% stenosis of carotid artery can carotid
endarterectomy plus best medical therapy reduce outcomes of major stroke or death
over next two years compared with best medical therapy alone?
Question
General practice and private acupuncture clinics in UK Volunteer academic and specialist hospitals with multidisciplinary
neurological-neurosurgical teams and high procedure volumes with low mortality in
US and Canada
Setting
Anyone aged 18-65 with non-specific low back pain of 4-52
weeks’ duration who were judged to be suitable by their
general practitioner. There were some exclusion criteria,
eg those with spinal disease
Symptomatic patients stratified for carotid stenosis severity, with primary interest in
severe carotid stenosis (high risk) group, who were thought to be most likely to
respond to endarterectomy. Exclusions included mental incompetence and another
illness likely to cause death within 5 years. Patients also were temporarily ineligible
if they had any of seven transient medical conditions (eg, uncontrolled hypertension
or diabetes)
Participants
Acupuncturists determined the content and number of
treatments according to patients’ needs
Endarterectomy had to be carried out (rather than stenting or some other operation),
but the surgeon was given leeway in how it was performed. Surgeons had to be
approved by an expert panel, and were restricted to those who had performed at
least 50 carotid endarterectomies in the past 24 months with a postoperative
complication rate (stroke or death within 30 days) of less than 6%. Centre compliance
with the study protocol was monitored, with the chief investigator visiting in the case
of deficiencies
Intervention
Primary outcome was bodily pain as measured by SF-36.
Secondary outcomes included use of pain killers and
patient satisfaction
The primary outcome was time to ipsilateral stroke, the outcome most likely to be
affected by carotid endarterectomy. Secondary outcomes: all strokes, major strokes,
and mortality
Outcomes
Direct—general practitioners and patients can immediately
use the trial results in their decision making
Indirect—patients and clinicians are highly selected and it isn’t clear how widely
applicable the results are
Relevance to
practice
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RESEARCH METHODS & REPORTINGTable 3| Checklist of items for reporting pragmatic trials
Extension for pragmatic trials Standard CONSORT description Item Section
How participants were allocated to interventions (eg, “random
allocation,” “randomised,” or “randomly assigned”)
1 Title and abstract
Introduction
Describe the health or health service problem that
the intervention is intended to address and other
interventions that may commonly be aimed at this
problem
Scientific background and explanation of rationale 2 Background
Methods
Eligibility criteria should be explicitly framed to show
the degree to which they include typical participants
and/or, where applicable, typical providers (eg,
nurses), institutions (eg, hospitals), communities (or
localities eg, towns) and settings of care (eg, different
healthcare financing systems)
Eligibility criteria for participants; settings and locations where the
data were collected
3 Participants
Describe extra resources added to (or resources
removed from) usual settings in order to implement
intervention. Indicate if efforts were made to
standardise the intervention or if the intervention and
its delivery were allowed to vary between participants,
practitioners, or study sites
Precise details of the interventions intended for each group and how
and when they were actually administered
4 Interventions
Describe the comparator in similar detail to the
intervention
Specific objectives and hypotheses 5 Objectives
Explain why the chosen outcomes and, when
relevant, the length of follow-up are considered
important to those who will use the results of the trial
Clearly defined primary and secondary outcome measures and, when
applicable, any methods used to enhance the quality of
measurements (eg, multiple observations, training of assessors)
6 Outcomes
If calculated using the smallest difference considered
important by the target decision maker audience (the
minimally important difference) then report where
this difference was obtained
How sample size was determined; explanation of any interim analyses
and stopping rules when applicable
7 Sample size
Method used to generate the random allocation sequence, including
details of any restriction (eg, blocking, stratification)
8 Randomisation—sequence
generation
Method used to implement the random allocation sequence (eg,
numbered containers or central telephone), clarifying whether the
sequence was concealed until interventions were assigned
9 Randomisation—allocation
concealment
Who generated the allocation sequence, who enrolled participants,
and who assigned participants to their groups
10 Randomisation—implementation
If blinding was not done, or was not possible, explain
why
Whether participants, those administering the interventions, and those
assessing the outcomes were blinded to group assignment
11 Blinding (masking)
Statistical methods used to compare groups for primary outcomes;
methods for additional analyses, such as subgroup analyses and
adjusted analyses
12 Statistical methods
Results
The number of participants or units approached to
take part in the trial, the number which were eligible,
and reasons for non-participation should be reported
Flow of participants through each stage (a diagram is strongly
recommended)—specifically, for each group, report the numbers of
participants randomly assigned, receiving intended treatment,
completing the study protocol, and analysed for the primary outcome;
describe deviations from planned study protocol, together with
reasons
13 Participant flow
Dates defining the periods of recruitment and follow-up 14 Recruitment
Baseline demographic and clinical characteristics of each group 15 Baseline data
Number of participants (denominator) in each group included in each
analysis and whether analysis was by “intention-to-treat”; state the
results in absolute numbers when feasible (eg, 10/20, not 50%)
16 Numbers analysed
For each primary and secondary outcome, a summary of results for
each group and the estimated effect size and its precision (eg, 95%
CI)
17 Outcomes and estimation
Address multiplicity by reporting any other analyses performed,
including subgroup analyses and adjusted analyses, indicating which
are prespecified and which are exploratory
18 Ancillary analyses
All important adverse events or side effects in each intervention group 19 Adverse events
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RESEARCH METHODS & REPORTINGTable 3 (continued)
Extension for pragmatic trials Standard CONSORT description Item Section
Discussion
Interpretation of the results, taking into account study hypotheses,
sources of potential bias or imprecision, and the dangers associated
with multiplicity of analyses and outcomes
20 Interpretation
Describe key aspects of the setting which determined
the trial results. Discuss possible differences in other
settings where clinical traditions, health service
organisation, staffing, or resources may vary from
those of the trial
Generalisability (external validity) of the trial findings 21 Generalisability
General interpretation of the results in the context of current evidence 22 Overall evidence
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RESEARCH METHODS & REPORTING